Cytostatic Drug Resistance in Childhood Relapsed Acute Lymphoblastic Leukemia

  • E. Klumper
  • R. Pieters
  • G. J. L. Kaspers
  • A. H. Loonen
  • D. R. Huismans
  • C. H. van Zantwijk
  • K. Hählen
  • E. R. van Wering
  • G. Henze
  • A. J. P. Veerman
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)

Abstract

The treatment of childhood acute lymphoblastic leukemia (ALL) has improved greatly in recent decades. At present, dependent on the risk group, 82% to 100% of the children with ALL will achieve a complete remission (CR) when treated with combination chemotherapy [1]. Overall, about two-thirds will remain in continuous complete remission (CCR). Despite of the current available effective cytostatic drugs, still one-third will get a relapse. Patients suffering from a relapse do have a poor prognosis in which drug resistance of leukemic cells is supposed to playa major role [2].

Keywords

Leukemia Doxorubicin Glucocorticoid Cytosine Anthracenedione 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Miller DR, Miller LP (1990) Acute lymphoblastic leukemia in children: an update of clinical, biological. and therapeutic aspects. Critical Reviews in Oncology/Hematology 10: 131–164PubMedCrossRefGoogle Scholar
  2. 2.
    Hall A, Cattan AR, Proctor SJ (1989) Mechanisms of drug resistance in acute leukaemia. Leuk Res 13: 351–356PubMedCrossRefGoogle Scholar
  3. 3.
    Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER, Veerman AJP (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 338: 399–403PubMedCrossRefGoogle Scholar
  4. 4.
    Veerman AJP, Pieters R (1990) Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 74: 381–384PubMedCrossRefGoogle Scholar
  5. 5.
    Hongo T, Fujii Y, Igarashi Y (1990) An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia. Cancer 65: 1263–1272PubMedCrossRefGoogle Scholar
  6. 6.
    Kaspers GJL, Pieters R, van Zantwijk CH, de Laat PAJM, de Waal FC, van Wering ER, Veerman AJP (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64: 469–474PubMedCrossRefGoogle Scholar
  7. 7.
    Pieters R, Huismans DR, Leyva A, Veerman AJP (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 59: 217–220PubMedCrossRefGoogle Scholar
  8. 8.
    Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hahlen K, Veerman AJP (1990) In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76: 2327–2336PubMedGoogle Scholar
  9. 9.
    Pieters R, Huismans DR, Leyva A, Veerman AJP (1988) Adaptation of the rapid automated tetrazolium dye based (MTT-) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41: 323–332PubMedCrossRefGoogle Scholar
  10. 10.
    Behrendt H (1991) The significance of relapse in childhood acute lymphoblastic leukemia. PhD thesis, Rodopi, AmsterdamGoogle Scholar
  11. 11.
    Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hahlen K, Veerman AJP (1992) Different types of non-p-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 65: 691–697PubMedCrossRefGoogle Scholar
  12. 12.
    Livingston RB, Carter SK (1970) Single agents in cancer chemotherapy. IFI/Plenum, New York Washington LondonGoogle Scholar
  13. 13.
    Buchanan GR (1990) Diagnosis and management of relapse in acute lymphoblastic leukemia. Hematol/Oncol Clin North Am 4: 971–995Google Scholar
  14. 14.
    Graham ML, Estrada J, Ragab AH, Starling KA, Rosen D, Wilkerson RW (1991) Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood: A pediatric oncology group study. Invest New Drugs 9: 263–267PubMedCrossRefGoogle Scholar
  15. 15.
    Starling KA, Mulne AF, Vats TS, Schoch I, Dukart G (1985) Mitoxantrone in refractory acute leukemia in children: A phase I study. Invest New Drugs 3: 191–195PubMedCrossRefGoogle Scholar
  16. 16.
    Fessas P, Wintrobe MM, Thompson RB, Cartwright GE (1954) Treatment of acute leukemia with cortisone and corticotropin. Arch Int Med 94: 384–401CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • E. Klumper
    • 1
  • R. Pieters
    • 1
  • G. J. L. Kaspers
    • 1
  • A. H. Loonen
    • 1
  • D. R. Huismans
    • 1
  • C. H. van Zantwijk
    • 1
  • K. Hählen
    • 2
  • E. R. van Wering
    • 3
  • G. Henze
    • 4
  • A. J. P. Veerman
    • 1
    • 3
  1. 1.Department of PediatricsFree University HospitalAmsterdamThe Netherlands
  2. 2.Department of PediatricsSophia’s Children HospitalRotterdamThe Netherlands
  3. 3.Dutch Childhood Leukemia Study GroupThe HagueThe Netherlands
  4. 4.Department of PediatricsFree UniversityBerlinGermany

Personalised recommendations